Parvovirus formulation for treating tumors
US-10624935-B2 · Apr 21, 2020 · US
Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
US11964015B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11964015-B2 |
| Application number | US-202117226199-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 9, 2021 |
| Priority date | Apr 1, 2016 |
| Publication date | Apr 23, 2024 |
| Grant date | Apr 23, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating cancer comprising administering a pharmaceutical combination containing (a) parvovirus H-1 and (b) an anti-PD1 antibody or an anti-PD-L1 antibody. 2. The method according to claim 1 , wherein (a) parvovirus H-1 and (b) the anti-PD1 antibody or the anti-PD-L1 antibody are sequentially administered. 3. The method according to claim 1 , wherein the method comprises treating solid tumors, haematological cancer and/or cancer initiating stem cells. 4. The method according to claim 1 , wherein the cancer is brain cancer, colon cancer, bladder cancer, liver cancer, breast cancer, kidney cancer, head/neck squamous cell carcinoma, lung cancer, malignant melanoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer or stomach cancer. 5. The method according to claim 4 , wherein the brain cancer is glioblastoma multiforme. 6. The method according to claim 1 , wherein (a) parvovirus H-1 and/or (b) the anti-PD1 antibody or the anti-PD-L1 antibody are administered by intratumoral or intravenous administration.
Assignees
Inventors
Classifications
- A61K39/39541Primary
against normal tissues, cells · CPC title
- A61K35/768Primary
Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766 · CPC title
- A61K39/3955Primary
against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11964015B2 cover?
- The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.
- Who is the assignee on this patent?
- Deutsches Krebsforsch, Univ Heidelberg Ruprecht Karls
- What technology area does this patent fall under?
- Primary CPC classification A61K39/39541. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).